These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11365914)

  • 21. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRIA clinical trials.
    Newsline People AIDS Coalit N Y; 1998 Sep; ():59. PubMed ID: 11367496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indinavir (Crixivan): new packaging and strength.
    Res Initiat Treat Action; 1999 Apr; 5(2):33. PubMed ID: 11366284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different combinations of ritonavir-indinavir.
    TreatmentUpdate; 2001 Sep; 13(5):1-2. PubMed ID: 11768859
    [No Abstract]   [Full Text] [Related]  

  • 25. Indinavir (Crixivan).
    Treat Rev; 1996 Apr; (no 21):7. PubMed ID: 11363398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple-drug therapy may mean lifelong commitment.
    AIDS Alert; 1999 Jan; 14(1):3-5. PubMed ID: 11366090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R
    Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral therapy: how simple can you get?
    Gilden D
    GMHC Treat Issues; 1998 Nov; 12(11):3-7. PubMed ID: 11365906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug research shows easier dosing, new combinations are making gains.
    AIDS Alert; 1998 Apr; 13(4):37-9. PubMed ID: 11365139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ritonavir/indinavir combination study shows promising dosing results.
    AIDS Patient Care STDS; 1998 Feb; 12(2):146-7. PubMed ID: 11361915
    [No Abstract]   [Full Text] [Related]  

  • 32. Protease inhibitors at a glance...
    Notes Undergr; 1998-1999 Winter; (No 38):suppl 1-4. PubMed ID: 11366198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crixivan, Norvir combination therapy studied.
    Strain W
    Posit Living; 1999 Apr; 8(3):16. PubMed ID: 12492057
    [No Abstract]   [Full Text] [Related]  

  • 34. Merck protease inhibitor available to persons with CD4 count 50 or less--must register by August 11.
    AIDS Treat News; 1995 Jul; (no 227):1-2. PubMed ID: 11362618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [More transparency facilities drug choice in general practice. Booster regimens in direct comparison].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():82. PubMed ID: 12043090
    [No Abstract]   [Full Text] [Related]  

  • 36. Hey, you can eat with Crixivan.
    Newsline People AIDS Coalit N Y; 1998 Jan; ():29. PubMed ID: 11367435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C; Myrto A; Marcelin AG; Ghosn J; Ait-Mohand H; Schneider L; Agher R; Bricaire F; Costagliola D; Calvez V; Peytavin G; Katlama C
    Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
    Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.